to December thanks filed the and Yesterday, ended Thank everyone for you, calling XXXX. and our XX, we Nasrat, XX-Q months today. quarter X in the
So December provide The third March the and section our XX, of which ended to fiscal sec.gov is our we're of year. fiscal and available that year, the year filings. links websites the is March on is means fiscal as the on Investors XXXX quarter Q XXst XXXX. our well many a that elitepharma.com, website, other That's quarter as
elitepharma.com you the if from through the yet, a So other sites. Q gone or please of haven't get usual any copy
about. and there's some There's a numbers. these take the talk talk about I'd the of key into financials, to the in lot you those insight context financials, and through like I'll of analysis some providing a milestone, parts
and as As always, address comments we've do my and are to Elite well. I'll and that from shareholders received financials questions related followers, those best
just with we $X.X to the for start hard let's quarter. quarter I So to milestone for XXXX reached compared the and P&L, achieve. Revenues it's that we've mentioned, were a milestone million where December as working $X.X the million December been
crossed the checked an operations. last compared per -- this pushed quarter was years that million time one, also a ongoing different. we've a $X This that due it But had it's milestone first around item. above that onetime we to $X revenues that's was and So just a million. I where the as X one-time to quarter that is ago, was mark there increase quarter, from quarter year, XX% and
fees. earned event, from revenues revenues the $X and licensing rather onetime As but million from in manufacturing not was a
We partners usual everyone great goes to for effort our by Elite face in by making both at credit a their the challenges and industry. our as faced our in still performance. regulatory as well team all and competitive products marketing So shipping
us we an that were to still of XXXX's revenues the couple quarters even a in level. revenues million September out were earned higher nice, but the above approximately for achieve also $X.X good our XX%, at cut during is So XXXX have December work quarter.
So to we went December compared XX% up as September. during
a But achieved grew June just the And in you revenues. and on want million little before we total just reasons We what's in March are $X.X December into million in these drill clear. So that, quarter, I'm revenues, in were come to how from $X.X numbers we I revenues. a quarters, do growing starting $X.X causing the hit if down I September, there the going to go we've we of quarter. quarter, Then far $X.X million. this few to and XXXX revenues the with now, to the down in summarize million at
Adderall, of as The the lifeblood launched of new launch demonstrate Namely, generic talk part is especially got immediate and these I of Adderall we in during expect, the products the and we that. R&D mentioned, Dantrolene. might so We products, being factor one year. new fiscal When you pharmaceutical true, But stream. release always launched the revenue immediate just generic is that products bump manufacturing the that's revenues. quarters of and past about Generic an we've company few this as results biggest a always
manufacturing part is other The addition the in profit split. to revenues
when natural the market revenues call, there's the and Now this subject during sold is product end our fully two but this the on is market I that takeaway for many lag six profit product split about the partners. earned be as market. a is the manufacturing by as are user and to when It in talked earned. last into our to quarters as between between sold split takes profit
Since be which and in are which splits, by marked manufacturing revenues period that is a there which profit the product in-market it's are the product sales will profit when by shipment between earned, is splits drive marked sales. lag period this in-market earned,
a sold market. come or launched exactly that's and when the starting generic quarter after now We as are we and manufacturing online revenues And they're So we Dantrolene, Adderall profits recorded happening. what's X shipped. the to in
the these phentermine, to had products, significantly. and new Isradipine existing old So has the well we've that very they products in done naltrexone, steady and remain grown products, addition
almost together you and revenues, get just tripling $X that quarter. are which quarters So you million X and all our first put in
from Before X other moving on to factors. I revenues, note want
First, new the the Adderall a still and they've and generic a still job release that X relatively market, market launched so great available. through of it immediate still in But partner, more share barely than growth far. was marketing Lannett, is is -- Adderall lot ago there's our months done with
to full potential it's yet clear So will we've not tell. the whether as Time seen product. this of
of our revenue. December. yet recently has impacted not second the that is extended-release that generic that approved Adderall, approved in The factor And got
any December Adderall. extended-release these include from product, contribution don't So that generic financials
to Now its we've revenues Adderall extended-release own future on our profits. contribution to has seen financials, positive the impact that immediate the is release expected and product and generic provide had
this business So And to from again, the lagged remember generic revenue also the how Adderall. profits that earned model the manufacturing applies extended-release fits revenues. product, behind
more something So But thing Everybody the talking for revenue any I also single more than One revenues. we're revenue our achieved quarterly future the I on in XXXX. and period and year-to-date $XX ended we expect, usually X to in more XX, the this the calls don't mention, XXXX, just $XX months than have something in same for I'll the million on is It's year. revenues next revenues, on revenues. million double, X-month year-to-date the be focus expect in million that's I likes about. is over the $X.X year, and December in
months, months X record, just to full and after a have X So eclipsed go. we've more already year we still
So moving the P&L. down
$X.X just was which development, and XXXX $X December research for million quarter, quarter. December year's to compared come to for as under We December this the million XXXX
new timing Now has and as see decrease XXXX and been heavily a a in that the in extended-release we point turning or decreased reflect R&D. are R&D quarters of here quarter future and Nasrat bio activities studies in and costs that the it's viewed XXXX, investment higher cost much bio of and financial a as that's a in due on studies not than takeaway benchmark development more more dollars invested activities. release of trials indicative the view, spent the out. should from The we talk of trend, correlating But costs and Adderall to generic was R&D how is less the be but of not products, these actual incurred. we immediate December will expect to detail
$X.X We to that be million haven't an an loss P&L. December come to talked word a I long was something long operating time. I the compared down for said that of moving profit and the XXXX It's the for haven't $XXX,XXX which as about operating a in So would time, quarter. profit,
on which profits any we that do in around that's profitability. And contribution please extended-release generic from launch turnaround Adderall, are revenues to of are we So keep other pipeline. R&D these way, million insignificant include not in Also, not and that the also a which products expect going shortly. in mind $X.X some even horizon, develop there's as our the more significant costs
be So results there's future usual going challenges, effects and developments. also There's their and we face, those also that for will incurred which competitive costs the regulatory on to have profits.
quarter XXXX many always was consider record factors are for the through to Elite. one there the summary, we million broke there the a $X In It's mark. which So quarter in are. December revenue for as future,
any months fiscal nine exceeded have results year-to-date. single The also
that which And just statement. just into months but really still XXXX revisit comments. first in would and the is several now, And was past, getting I calls before something I year, had derivative talk a go. in it years. about and the before I mentioned fiscal today I on thing. got now one thought is address the profit, the we them to already be to we We've good a values, that. And So more record I P&L day wanted our so to to Nasrat, with operating showed haven't to breaking in over a have turn I Q&A. talked wanted which -- about quarterly some do for It's it change X many to
another statement, If our other in you section, have other and below P&L income the the expense look at we line.
derivative -- have an over $X.X almost of million. in expense We just fair value $X have a million of change we instrument,
So are to our warrants. that balance on has every value which our the warrants with do And quarter, we sheet.
using dependent stock is valued the model. price. valuation This Essentially, Black-Scholes this quarter, the upon we underlying
-- price. is have worth then warrants the have less as If and warrants revenue. So stock This work the between to we an we way if Black-Scholes up, a will goes and correlation stock book is book down, more, price revenues known the are stock goes and what's price the the expense. works negative
cases, is, any be never if cash will never, cash payments. in record we flip any all the there we received. if And expense, will be revenue, never So an side there record
exercise There the these the our either through end of any or item equity. warrants valuations never So expiration record eventually, will any is in, -- ever coming an both be the retired, be in where of will liability up, up the warrants, out. in will be price the warrants, stock cash an if expense. will we cash going goes This there nor cases,
like most the paid If for And see revenues. up. we then go see, unfortunately, will for to like the revenue, to to goes price get So we a have nor ever of stock these to will get book don't price us but expenses. down, that we pay we stock never
up and well. know at questions a our that so I'll looking everybody, time, that will I on keep I'm as satisfy it quarters please for I to that mind, being, hope you're when of of time get couple bring lot financial a sure, from I in the in So again, time statements,
it that's for So me.
like Now CEO, and President Mr. Hakim. introduce and to our Chairman I'd Nasrat
